A5053535513- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Statistical Methods in Clinical Trials
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Hormonal and reproductive studies
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Global Cancer Incidence and Screening
- Multiple and Secondary Primary Cancers
- Multiple Myeloma Research and Treatments
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- COVID-19 and healthcare impacts
- Estrogen and related hormone effects
- Health Systems, Economic Evaluations, Quality of Life
- Ovarian cancer diagnosis and treatment
- Bone health and treatments
Duke Medical Center
2016-2025
Duke University
2016-2025
Duke Cancer Institute
2013-2025
Duke University Hospital
2016-2025
National Cancer Institute
1999-2024
Alliance Data (United States)
2014-2024
Sidney Kimmel Comprehensive Cancer Center
2004-2024
Northwestern University
2006-2024
United Arab Emirates University
2024
Clinical Research Institute
2022-2024
Purpose To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer castrate levels of testosterone. Methods A committee investigators experienced conducting defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria Solid Tumors (RECIST), emerging trial data. Results The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving,...
Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations succeed those from prior Prostate Cancer Clinical Trials Working Groups.An international expert committee of investigators (the Group 3 [PCWG3]) was reconvened expanded met in 2012-2015 formulate updated criteria on basis emerging data validation studies 2 recommendations.PCWG3...
Experimental studies in animals and observational humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, precursors to most cancers.
PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes PSA will often antedate bone scan. Furthermore, many but not all investigators have observed an association between decline levels of 50% or greater survival. Since the majority phase II clinical trials for androgen-independent cancer (AIPC) used as marker, we believed it was important to agree on definitions values...
PURPOSE: Approximately 40,000 men die each year of hormone-refractory prostate cancer (HRPC). The results treatment with chemotherapy have been disappointing to date, no trials demonstrating a benefit respect survival duration. Corticosteroids and mitoxantrone shown be active agents in this disease. purpose study was demonstrate an advantage hydrocortisone (M+H) over alone PATIENTS AND METHODS: Two hundred forty-two patients HRPC were randomized receive either M+H or alone. Patients...
Purpose Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus monotherapy was conducted. Patients Methods with previously untreated, clear-cell RCC were randomly assigned receive either (10 mg/kg intravenously every 2 weeks) (9 million U subcutaneously three...
To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients (HRPC).Data from six Cancer Leukemia Group B protocols enrolled 1,101 with adenocarcinoma of during study period 1991 2001 were pooled. The proportional hazards was multivariable on basis pretreatment factors construct prognostic model. area under receiver operating characteristic curve (ROC) calculated as measure predictive discrimination....
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozantinib compared with sunitinib as first-line in patients mRCC. Patients Methods Eligible had untreated clear mRCC Eastern Cooperative Oncology Group performance status 0 to 2 were intermediate or poor risk per International Metastatic Renal Cell...
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
Purpose Antiandrogen withdrawal (AAWD) results in a prostate-specific antigen (PSA) response (decline PSA level of ≥ 50%) 15% to 30% androgen-independent prostate cancer (AiPCa) patients. Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect AAWD alone was compared simultaneous and K therapy. Patients Methods AiPCa patients were randomized undergo (n = 132), or together (400 mg orally [po] tid) hydrocortisone (30 po each...
A randomized, placebo-controlled study based on preclinical and clinical data that supports the potential role of vascular endothelial growth factor in prostate cancer was performed to evaluate addition bevacizumab standard docetaxel prednisone therapy patients with metastatic castration-resistant (mCRPC).
Prognostic models for overall survival (OS) patients with metastatic castration-resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in treatment options available these patients. This work developed validated an updated prognostic model to predict OS receiving first-line chemotherapy.Data from a phase III trial of 1,050 mCRPC were used (Cancer Leukemia Group B CALGB-90401 [Alliance]). The data randomly split into training testing sets. A separate served as...
To update the recommendations for use of bisphosphonates in prevention and treatment bone disease multiple myeloma. The Update Committee expanded guideline to include a discussion osteonecrosis jaw (ONJ).
Black men are more likely to die of prostate cancer than white men. In with similar stages disease, the contribution biological vs nonbiological differences this observed disparity is unclear.To quantify association black race long-term survival outcomes after controlling for known prognostic variables and access care among cancer.This multiple-cohort study included updated individual patient-level data clinical T1-4N0-1M0 from following 3 cohorts: Surveillance, Epidemiology, End Results...
The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met the primary end-point improving progression-free survival (PFS) assessed by investigator. We report PFS independent radiology review committee (IRC) assessment, ORR per IRC and updated overall (OS).Previously untreated patients RCC IMDC criteria were 1:1 to 60 mg daily 50 (4 weeks on/2 off). Stratification was group presence...
The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through use of accurate risk models or calculators. However, judging quality and acceptability a model is complex. AJCC Precision Medicine Core conducted 2‐day meeting to discuss characteristics necessary in cancer patients. More specifically, committee established inclusion exclusion criteria...
Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given previous reports suggested circulating tumor cell (CTC) AR-V7 detection poor prognostic indicator for the clinical efficacy of secondary hormone we conducted prospective multicenter validation study.PROPHECY ( ClinicalTrials.gov identifier: NCT02269982) multicenter,...
Innovations in treatments, imaging, and molecular characterisation advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some these topics supplement guidelines based on level 1 evidence.To present the results from APCCC 2019.Similar prior conferences, experts identified 10 important areas controversy regarding cancer:...
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for ten most important areas of controversy in advanced prostate cancer (APC) management. successful registration several drugs castration-resistant recent studies chemo-hormonal therapy men with castration-naïve have led to considerable uncertainty as best treatment choices, sequence options appropriate patient selection. Management recommendations based on...